Center for Mind and Brain, University of California, Davis.
Department of Psychology, San Diego State University, San Diego, California.
JAMA Psychiatry. 2020 Oct 1;77(10):1031-1043. doi: 10.1001/jamapsychiatry.2020.0431.
Recent estimates suggest that more than 50% of all deaths worldwide are currently attributable to inflammation-related diseases. Psychosocial interventions may represent a potentially useful strategy for addressing this global public health problem, but which types of interventions reliably improve immune system function, under what conditions, and for whom are unknown.
To address this issue, we conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) in which we estimated associations between 8 different psychosocial interventions and 7 markers of immune system function, and examined 9 potential moderating factors.
PubMed, Scopus, PsycInfo, and ClinicalTrials.gov databases were systematically searched from February 1, 2017, to December 31, 2018, for all relevant RCTs published through December 31, 2018.
Eligible RCTs included a psychosocial intervention, immune outcome, and preintervention and postintervention immunologic assessments. Studies were independently examined by 2 investigators. Of 4621 studies identified, 62 were eligible and 56 included.
Data were extracted and analyzed from January 1, 2019, to July 29, 2019. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline was followed. Data were extracted by 2 investigators who were blind to study hypotheses and analyses, and were then analyzed using robust variance estimation. Analysis included 8 psychosocial interventions (behavior therapy, cognitive therapy, cognitive behavior therapy [CBT], CBT plus additive treatment or mode of delivery that augmented the CBT, bereavement or supportive therapy, multiple or combined interventions, other psychotherapy, and psychoeducation), 7 immune outcomes (proinflammatory cytokine or marker levels, anti-inflammatory cytokine levels, antibody levels, immune cell counts, natural killer cell activity, viral load, and other immune outcomes), and 9 moderating factors (intervention type, intervention format, intervention length, immune marker type, basal vs stimulated markers, immune marker measurement timing, disease state or reason for treatment, age, and sex).
The primary a priori outcomes were pretest-posttest-control (ppc) group effect sizes (ppc g) for the 7 immunologic outcomes investigated.
Across 56 RCTs and 4060 participants, psychosocial interventions were associated with enhanced immune system function (ppc g = 0.30, 95% CI, 0.21-0.40; t50.9 = 6.22; P < .001). Overall, being randomly assigned to a psychosocial intervention condition vs a control condition was associated with a 14.7% (95% CI, 5.7%-23.8%) improvement in beneficial immune system function and an 18.0% (95% CI, 7.2%-28.8%) decrease in harmful immune system function over time. These associations persisted for at least 6 months following treatment and were robust across age, sex, and intervention duration. These associations were most reliable for CBT (ppc g = 0.33, 95% CI, 0.19-0.47; t27.2 = 4.82; P < .001) and multiple or combined interventions (ppc g = 0.52, 95% CI, 0.17-0.88; t5.7 = 3.63; P = .01), and for studies that assessed proinflammatory cytokines or markers (ppc g = 0.33, 95% CI, 0.19-0.48; t25.6 = 4.70; P < .001).
These findings suggest that psychosocial interventions are reliably associated with enhanced immune system function and may therefore represent a viable strategy for improving immune-related health.
重要性:最近的估计表明,目前全球超过 50%的死亡归因于与炎症相关的疾病。心理社会干预可能是解决这一全球公共卫生问题的一种潜在有效策略,但哪种类型的干预措施能够可靠地改善免疫系统功能,在什么条件下有效,以及对哪些人有效,这些都尚不清楚。
目的:为了解决这个问题,我们进行了一项系统评价和荟萃分析,评估了 8 种不同的心理社会干预措施与 7 种免疫系统功能标志物之间的关联,并检验了 9 个潜在的调节因素。
数据来源:从 2017 年 2 月 1 日至 2018 年 12 月 31 日,我们系统地检索了 PubMed、Scopus、PsycInfo 和 ClinicalTrials.gov 数据库,以查找截至 2018 年 12 月 31 日发表的所有相关随机临床试验(RCT)。
研究选择:合格的 RCT 包括心理社会干预、免疫结果以及干预前后的免疫评估。由两名研究人员独立检查研究。在确定的 4621 项研究中,有 62 项符合条件,56 项纳入分析。
数据提取和综合:数据从 2019 年 1 月 1 日至 2019 年 7 月 29 日提取和分析。遵循了系统评价和荟萃分析的首选报告项目(PRISMA)指南。由两名对研究假设和分析一无所知的研究人员提取数据,然后使用稳健方差估计进行分析。分析包括 8 种心理社会干预措施(行为疗法、认知疗法、认知行为疗法[CBT]、CBT 加附加治疗或增强 CBT 的模式、丧亲或支持性治疗、多种或联合干预、其他心理治疗和心理教育)、7 种免疫结果(促炎细胞因子或标志物水平、抗炎细胞因子水平、抗体水平、免疫细胞计数、自然杀伤细胞活性、病毒载量和其他免疫结果)和 9 个调节因素(干预类型、干预形式、干预时长、免疫标志物类型、基础与刺激标志物、免疫标志物测量时间、疾病状态或治疗原因、年龄和性别)。
主要结果和测量:主要的事先确定的结果是 7 种免疫结果的 pretest-posttest-control(ppc)组效应大小(ppc g)。
结果:在 56 项 RCT 和 4060 名参与者中,心理社会干预与增强免疫系统功能相关(ppc g=0.30,95%CI,0.21-0.40;t50.9=6.22;P<0.001)。总的来说,与对照组相比,随机分配到心理社会干预组的参与者的有益免疫系统功能改善了 14.7%(95%CI,5.7%-23.8%),有害免疫系统功能下降了 18.0%(95%CI,7.2%-28.8%)。这些关联至少持续 6 个月,且在年龄、性别和干预持续时间方面具有稳健性。这些关联在 CBT(ppc g=0.33,95%CI,0.19-0.47;t27.2=4.82;P<0.001)和多种或联合干预(ppc g=0.52,95%CI,0.17-0.88;t5.7=3.63;P=0.01)中最为可靠,且在评估促炎细胞因子或标志物(ppc g=0.33,95%CI,0.19-0.48;t25.6=4.70;P<0.001)的研究中也较为可靠。
结论和相关性:这些发现表明,心理社会干预与增强免疫系统功能可靠相关,因此可能是改善免疫相关健康的一种可行策略。